Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > New Press Release - Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive Officer
View:
Comment by Alamir1111 on May 24, 2023 6:55pm
Ceasers empire comes chrushing down  Where are our votes nobody asked ?
Comment by Alamir1111 on May 24, 2023 7:05pm
You pheasents  with millions of shares I declare you my subordinates pp will be
Comment by Alamir1111 on May 24, 2023 7:31pm
So one board member voted in favour rdw and   ceo resigns we got some power struggle going on.And you pheasents not included?strong message to market.15 pp
Comment by Longholder99 on May 24, 2023 7:54pm
What took them so long . Another dominoes.   
Comment by BlueFranky on May 24, 2023 8:04pm
As to what took them so long.. "Theralase has obtained the approval of the Toronto Stock Venture Exchange ("TSXV") to appoint Mr. DuMoulin-White as President"
Comment by Longholder99 on May 24, 2023 8:05pm
Excellent news.  I wonder whats next!
Comment by BlueFranky on May 24, 2023 8:07pm
Given his proclivity for promoting... I expect we'll be seeing a lot more of his vision in the coming months!
Comment by Alamir1111 on May 24, 2023 8:09pm
Pg rated 18
Comment by Alamir1111 on May 24, 2023 8:20pm
Hi maybe the  boy is going to grow some balls give him a chance
Comment by Yajne on May 24, 2023 9:48pm
I expect more NR's anytime now that the board has met to finalize Q1...among other things
Comment by Infinity on May 25, 2023 12:36am
About time!!
Comment by Oilminerdeluxe on May 25, 2023 1:09am
Hello there... Glad to see his bald head back. Hopefully the start of more things to come.
Comment by Lesalpes29 on May 25, 2023 6:46am
I don't know all the past story and I don't care much about the past! Time to focus on the coming months it should be exciting time for all shareholders. BTD-AA combo very soon! GL
Theralase Technologies Inc.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT

Visit Facebook Visit X Visit Linked In Visit Instagram Visit Youtube



INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250